Spongiotic Dermatitis

Stuart Millar Updated by Stuart Millar

Start Here:

Before using SmartLotion®, you must read this disclaimer.

We recommend reading these general instructions on how to use SmartLotion®: Click here.

Stinging can occur when first applying SmartLotion®. For instructions on how to reduce the stinging, please click here.


Red, itchy areas caused by fluid buildup in the skin that causes swelling. Can cause small rashes in the shape of coins.


Dr. Harlan treats his adult patients for spongiotic dermatitis by first having them apply SmartLotion® 3x per day for up to 4 weeks.

As long as the patient sees improvement during the initial 4 weeks, after 4 weeks he typically recommends tapering down to 2x per day for 2 weeks then to 1x per day for 2 weeks. The rate of tapering should vary based on how quickly the rash is healing.

He will often prescribe a corticosteroid to use with the SmartLotion® program until the rash is clear.

Dr. Harlan also insists that his spongiotic dermatitis patients apply a moisturizer 2x per day minimum. For a list of Dr. Harlan's recommended moisturizers, click here.

Additionally, Dr. Harlan recommends that his spongiotic dermatitis patients apply 15 minutes of UV light or sunshine per day to the affected area.


He says it is critical for his spongiotic dermatitis patients to keep moisturizing 2x per day, even when there is no rash present.

To prevent spongiotic dermatitis from returning, Dr. Harlan instructs his adult patients to apply SmartLotion® 1x per day, or less as needed.

Some patients require intervals of 2x and 1x every other day SmartLotion® applications for complete flare-up control. Some patients require 1 application per day, and some only require 3 applications per week.

This is why long-term safety was so important to Dr. Harlan when he formulated SmartLotion®. For whatever maintenance schedule his patients require, he wanted to ensure that there would be no chance of side effects. Rest assured, SmartLotion® is 100% safe for long term use, as demonstrated in his peer-reviewed safety study.

To read Dr. Harlan's peer-reviewed safety study, please click here.

How did we do?

Seborrheic Dermatitis

Stasis Dermatitis